168 related articles for article (PubMed ID: 34941058)
41. [Efficacy of lobaplatin plus S-1 and the predictive value of circulating tumor cell in patients with advanced gastric cancer].
Feng Q; Zhao JR; Zhang AX; Li SL
Zhonghua Zhong Liu Za Zhi; 2018 Sep; 40(9):696-702. PubMed ID: 30293397
[No Abstract] [Full Text] [Related]
42. Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604).
Tahara M; Fuse N; Mizusawa J; Sato A; Nihei K; Kanato K; Kato K; Yamazaki K; Muro K; Takaishi H; Boku N; Ohtsu A
Cancer Sci; 2015 Oct; 106(10):1414-20. PubMed ID: 26250827
[TBL] [Abstract][Full Text] [Related]
43. A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer.
Takahara N; Isayama H; Nakai Y; Sasaki T; Hamada T; Uchino R; Mizuno S; Miyabayashi K; Kogure H; Yamamoto N; Sasahira N; Hirano K; Ijichi H; Tateishi K; Tada M; Koike K
Cancer Chemother Pharmacol; 2013 Nov; 72(5):985-90. PubMed ID: 23995699
[TBL] [Abstract][Full Text] [Related]
44. A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma.
Li N; Wu T; Hong YG; Guo YZ; Cheng YF; Ma YJ; Bie LY; Cui DH; Gao XH; Tan BX; Li BS; Luo SX; Wang JS
BMC Med; 2022 Dec; 20(1):472. PubMed ID: 36482345
[TBL] [Abstract][Full Text] [Related]
45. A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer.
Huang JY; Xie XF; Chen XL; Zhang QY; Chen LP; Bai X; Lan XF; Song L; Guo JF; Du CW
Front Oncol; 2023; 13():1122294. PubMed ID: 37124484
[TBL] [Abstract][Full Text] [Related]
46. S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature.
Zhang C; Yu GM; Zhang M; Wu W; Gong LB
Medicine (Baltimore); 2020 Jan; 99(3):e18892. PubMed ID: 32011517
[TBL] [Abstract][Full Text] [Related]
47. Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial.
Zhu J; Song C; Zheng Z; Xia L; Chen Y; Ke G; Wu X
Front Oncol; 2021; 11():720343. PubMed ID: 34796105
[TBL] [Abstract][Full Text] [Related]
48. Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study.
Zhou B; Gong Q; Li B; Qie HL; Li W; Jiang HT; Li HF
J Clin Pharm Ther; 2022 May; 47(5):643-651. PubMed ID: 35023208
[TBL] [Abstract][Full Text] [Related]
49. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
[TBL] [Abstract][Full Text] [Related]
50. Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.
Umemura A; Nitta H; Sasaki A; Takahara T; Hasegawa Y; Wakabayashi G
Hepatogastroenterology; 2014 May; 61(131):814-20. PubMed ID: 26176079
[TBL] [Abstract][Full Text] [Related]
51. [Efficacy and safety of Xiaoaiping combined with chemotherapy in the treatment of advanced esophageal cancer].
Wang F; Fan QX; Wang HH; Han DM; Song NS; Lu H
Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):453-457. PubMed ID: 28635236
[No Abstract] [Full Text] [Related]
52. Radiotherapy plus temozolomide with or without anlotinib in H3K27M-mutant diffuse midline glioma: A retrospective cohort study.
Liu C; Kuang S; Huang T; Wu J; Zhang L; Gong X
CNS Neurosci Ther; 2024 Apr; 30(4):e14730. PubMed ID: 38644565
[TBL] [Abstract][Full Text] [Related]
53. A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma.
Tang Y; Ou Z; Yao Z; Qiao G
Medicine (Baltimore); 2019 Oct; 98(40):e17164. PubMed ID: 31577707
[TBL] [Abstract][Full Text] [Related]
54. Anlotinib as Monotherapy or Combination Therapy for Recurrent High-Grade Glioma: A Retrospective Study.
Yin J; Yin W; Zheng L; Li Y; Luo C; Zhang S; Duan L; Zhou H; Cheng K; Lang J; Xu K
Clin Med Insights Oncol; 2023; 17():11795549231175714. PubMed ID: 37435019
[TBL] [Abstract][Full Text] [Related]
55. Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).
Miyanaga A; Kubota K; Hosomi Y; Okuma Y; Minato K; Fujimoto S; Okamoto H; Satouchi M; Isobe H; Aono H; Takiguchi Y; Gemma A;
Jpn J Clin Oncol; 2019 Aug; 49(8):749-754. PubMed ID: 31070750
[TBL] [Abstract][Full Text] [Related]
56. [S-1 chemotherapy for cancer of the gastric tube used for esophageal reconstruction following surgery for esophageal cancer].
Motoyama S; Mori K; Maruyama K; Sato Y; Hayashi K; Usami S; Suzuki H; Ogawa J
Gan To Kagaku Ryoho; 2007 Dec; 34(13):2287-90. PubMed ID: 18079632
[TBL] [Abstract][Full Text] [Related]
57. [Efficacy and safety of anlotinib in 16 patients with advanced non-small cell lung cancer].
Si XY; Wang HP; Zhang XT; Wang MZ; Zhang L
Zhonghua Nei Ke Za Zhi; 2018 Nov; 57(11):830-834. PubMed ID: 30392239
[No Abstract] [Full Text] [Related]
58. Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.
Iwasa T; Tsurutani J; Watanabe S; Kato R; Mizuno Y; Kojima Y; Takashima T; Matsunami N; Morimoto T; Yamamura J; Ohtani S; Tanabe Y; Yoshinami T; Takano T; Komoike Y; Nakagawa K
BMC Cancer; 2019 Oct; 19(1):962. PubMed ID: 31619197
[TBL] [Abstract][Full Text] [Related]
59. Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis.
Peng PJ; Cheng H; Ou XQ; Zeng LJ; Wu X; Liu YM; Lin Z; Tang YN; Wang SY; Zhang HY; Chen ZB
Drug Des Devel Ther; 2014; 8():1083-7. PubMed ID: 25152614
[TBL] [Abstract][Full Text] [Related]
60. Investigation of a Novel S-1 Administration Schedule for Treating Metastatic and Recurrent Breast Cancer (KBCOG13).
Miki M; Takao S; Konishi M; Shigeoka Y; Miyashita M; Suwa H; Miyoshi Y; Hirokaga K; Okuno T; Yamagami K; Imamura M; Murase K; Yanai A; Tanino H
Anticancer Res; 2021 Jun; 41(6):3121-3126. PubMed ID: 34083305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]